PRGO250117C27500
- 0.05
- 0.000.00%
Perrigo Newsroom
Argus Research Downgrades Perrigo(PRGO.US) to Hold Rating
Piper Sandler Maintains Perrigo(PRGO.US) With Hold Rating
CCORF Maintains Perrigo(PRGO.US) With Buy Rating, Maintains Target Price $42
Perrigo Cut to Neutral From Overweight by Piper Sandler
Perrigo Price Target Cut to $27.00/Share From $34.00 by Piper Sandler
Perrigo Analyst Ratings
Piper Sandler Maintains Perrigo(PRGO.US) With Hold Rating, Maintains Target Price $27
Piper Sandler Downgrades Perrigo(PRGO.US) to Hold Rating, Cuts Target Price to $27
CCORF Maintains Perrigo(PRGO.US) With Buy Rating, Maintains Target Price $42
J.P. Morgan Maintains Perrigo(PRGO.US) With Buy Rating, Cuts Target Price to $38
Perrigo Company (PRGO) Receives a Buy From J.P. Morgan
Perrigo Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Perrigo(PRGO.US) With Buy Rating, Maintains Target Price $42
Buy Rating and $42 Target on Perrigo: Strategic Shift and Cost-Saving Initiatives Poised to Drive Margin Expansion
Perrigo Analyst Ratings
Piper Sandler Maintains Perrigo(PRGO.US) With Buy Rating, Maintains Target Price $35
Perrigo Company (PRGO) Gets a Buy From Piper Sandler
Organon Downgraded, Amneal Upgraded as J.P. Morgan Reviews Specialty Pharma
CCORF Maintains Perrigo(PRGO.US) With Buy Rating, Maintains Target Price $42
Analysts Have Conflicting Sentiments on These Healthcare Companies: Perrigo Company (PRGO), Cue Biopharma (CUE) and United Therapeutics (UTHR)